FINWIRES · TerminalLIVE
FINWIRES

Teradyne, GS Microelectronics Enter Partnership to Establish Testing Facility

By

Teradyne (TER) entered a multi-year partnership with GS Microelectronics to develop a semiconductor testing center to accelerate engineering support for clients building devices across AI, automotive, power management, and silicon photonics, the provider of semiconductor services said in a Tuesday statement.

Under the deal, GS Microelectronics will deploy Teradyne's automated test platforms within a dedicated facility, expected to be inaugurated in Q4, to support device evaluation, pilot production, and technical training, according to the statement.

The companies will also partner through joint sales engagements, target account development, technical workshops, and client briefings, according to GS Microelectronics.

Price: $393.09, Change: $+11.55, Percent Change: +3.03%

What else is happening in Wire?

Wire

Inghams Group Says Mitsubishi UFJ Financial's Stake in Firm Falls

Inghams Group (ASX:ING) said Mitsubishi UFJ Financial Group's voting power in the firm fell to 6.19% from 7.2% as of Sept. 16, according to a Tuesday Australian bourse filing.The Japanese bank holds nearly 23 million ordinary shares of the firm as of Sept. 16.Inghams Group's shares fell past 1% in recent trading on Tuesday.

ASX:ING
Wire

AnaptysBio Swings to Q2 Profit as Revenue Rises; Shares Gain After Hours

AnaptysBio (ANAB) reported Q2 net income late Monday of $5.11 per diluted share, swinging from the loss of $1.30 a year earlier.Revenue in the three months ended June 30 rose to $27.5 million from $22.3 million a year earlier.The company's shares rose 4.5% in after-hours trading.

$ANAB
Wire

Moderna Provides Details on Data Presentations at Upcoming Conferences

Moderna (MRNA) said Monday that phase 3 data for intismeran autogene in resected stage IIB-IV melanoma will be presented at a Presidential Symposium during the ESMO Congress 2026 on Oct. 24.The company said three abstracts on the investigational individualized neoantigen therapy were accepted for presentation, including data from a phase 1 pancreatic cancer study and a phase 3 lung cancer study.The company will also present in the Bernstein Insights Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum on Sept. 23, according to its website.Price: $173.39, Change: $+19.35, Percent Change: +12.56%

$MRNA